And so physicians today, if they were so inclined, could draw a tube of blood and send it off to Foundation or to Guardant for analysis. And these panels today will pick up the secondary mutations seen in just patients and report back on that. So physicians, if they so chose €“ to do so, they could run that analysis and then make treatment decisions which would be off-label today. So this isn’t something that we can or would promote to. But physicians could then make treatment decisions and they would have to work with the patient’s insurance provider to obtain coverage for that off-label use. But I guess my point is just that these diagnostics are available today for physicians who are interested in understanding the secondary mutation status for their patients.
Matt, do you want to comment then on vimseltinib in MOTION?
Matt Sherman: Yes, good morning, Nicole. So, yes, as you know for the 25-week endpoint in the vimseltinib, TGCT study, we had a 38% response rate, which was similar to what was reported for the ENLIVEN, pexidartinib study and then they’re labeled. But also as we also know, these patients continue on therapy for longer than six months and can have a response beyond that. And we reported for the Phase 1 dose escalation cohorts who were on study the longest a 69% overall response rate in the TGCT patients in the Phase 1/2 study. And in terms of a label, it’s also you can €“ it’s also noted that ENLIVEN’s label or pexidartinib label based ENLIVEN study also shows their overall response rate in the open label portion of the study. And that’s 61% in the current label for pexidartinib. So we could expect that our label for vimseltinib may contain some longer-term follow up and a higher overall response rate.
Nicole Gabreski: Great. Thanks.
Operator: Please stand by for our next question. Our next question comes from Brad Canino with Stifel. Your line is now open.
Brad Canino: Good morning and thank you. Steve, maybe a follow-up on your previous comments. I guess I want to know, based on the KOL and physician feedback to the subgroup analysis, do you expect the material enough proportion of practices to adopt a second line ctDNA guided treatment paradigm in the next few years to impact QINLOCK sales? And then a second question with the top line readout for vimseltinib slated for 4Q. When you think about the degree of data that you would include in the package to the FDA is successful, can you add any comments about how long you expect it to take to reach an NDA filing? Thank you.
Steve Hoerter: Yes, thanks, Brad. Two good questions. So with respect to expectations around taking the data that we’ve presented at ASCO and that being translated or changing practice today it’s an uncertainty. So of course we can’t promote to that use. We don’t have extensive market research that tells us whether physicians will adopt the use of the drug on an off-label basis. What we’ve seen so far in our experience is that use has been for QINLOCK has been generally within our approved label. So we’ll continue to monitor and understand how physicians, if they choose to change practice, how that practice changes over time. But we don’t have any information at the moment with respect to what changes might occur. Clearly having a label in the second line setting in this patient population is what will ultimately allow us to drive share and drive utilization.
